Effect of the combined use of monensin with virginiamycin or bacitracin on beef cattle performance, liver gluconeogenesis, lipid metabolism and intramuscular fat content

Abstract

The objective was to evaluate the combined use of monensin with virginiamycin or zinc bacitracin on performance, serum D-lactate, feeding behavior, carcass traits, and the expression of gluconeogenic and lipogenic genes over time in feedlot young bulls. Nellore × Angus (F1) young bulls (n = 72; BW 368 ± 16.3 kg) were used in a completely randomized design. Animals were stratified by BW and allotted into 18 pens with 4 animals each. Pens (6 pens per treatment) were randomly assigned to the following treatments: monensin (MON), monensin + zinc bacitracin (MONZB) and monensin + virginiamycin (MONVM). The doses of monensin, zinc bacitracin and virginiamycin were 18.9, 6.62 and 18.9 mg/kg DM of the diet, respectively. The diet consisted of 85% corn-based concentrate and 15% corn silage. The finishing phase was 109 days with the first 27 days for diet adaptation and the remaining 82 days for the finishing diet. Treatment additives did not affect body weight (BW), overall average daily gain (ADG), dry matter intake (DMI) or gain:feed (P ≥ 0.13). Animals fed MONVM had lesser (P = 0.03) intramuscular fat than those fed MON and MONZB. Serum D-lactate concentration was greater (P = 0.05) in MONVM animals than in MON and MONZB animals. In the liver, MONVM animals upregulated (P < 0.03) Pyruvate carboxylase (PC) and Lactate dehydrogenase A (LDHA) expression compared with MON and MONZB. The expression of Peroxisome proliferator-activated receptor gamma (PPARG) in LT tended to be decreased (P = 0.07) in MONVM animals than in MONZB. Animals fed MONVM downregulated (P = 0.03) Acetyl-CoA carboxylase alpha (ACACA) expression compared with those fed MON. In conclusion, these additives affect growth performance in different times during feedlot phase. The combined use of monensin and virginiamycin reduce lipogenesis and increase lipid oxidation, triggering lesser IMF deposition compared to monensin alone or combined with bacitracin.